Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorSpine Centre of Southern Denmark

About this trial

The purpose of this randomized double-blind clinical trial is to determine the efficacy of percutaneous vertebroplasty (PVP) in relieving severe pain in patients with MRI-verified acute or sub-acute osteoporotic vertebral compression fractures (OVCFs) compared to sham as well as examine the socio-economic implications associated with performing vertebroplasty.

The primary outcome is improvement of pain intensity as measured on a Visual Analog Scale (VAS, 0 to100) 12 weeks after treatment. Secondary outcomes include patient-reported back-related disability, patient-reported quality of life, spinal sagittal balance, complications associated with the procedure, incidence of new OVCFs and socioeconomic costs.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 50+ and diagnosed with symptomatic osteoporotic spinal compression fractures between T6 and L5 (incl).

Focal tenderness on the level of the vertebral fracture.

Fractures verified with oedema of the relevant vertebra on the MRI STIR sequence

Osteoporotic Fractures type 1-4.

Disqualifiers

- Contra-indications for spine surgery.

Platelets < 30 mia/l.

Osteoporotic Fractures type 5 and Pincer-type.

Complete collapse of the vertebral body precluding insertion of needle.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Vertebroplasty

    Procedure/Surgery

    PVP

  • Sham Vertebroplasty

    Procedure/Surgery

    Sham PVP

Treatment groups

240 Participants
are divided into 2 treatment groups
Group A: VertebroplastyActive comparator 1 intervention
Group B: Sham vertebroplastySham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Pain intensity using the 100-point VAS

Self-reported average pain intensity over the previous 24 hours, using the 100-point VAS will be recorded at time of randomization and after 1, 2, 3, 4 and 5 days, and after 2, 4, 8 and 12 weeks, and finally at 12 months and 24 months post-randomization

Time frame
VAS will be recorded at time of randomization and after 1, 2, 3, 4 and 5 days, and after 2, 4, 8 and 12 weeks, and finally at 12 months and 24 months post-randomization

Secondary outcomes

1

Patient-reported disability.

The patients rate their disability at the time of enrolment and at 4 and 12 weeks, 12 and 24 months post-randomization using the Oswestry Disability Index (ODI) questionnaire

Time frame
Recorded at enrolment and at 4 and 12 weeks, 12 and 24 months post-randomization
2

Health-related quality of life.

HRQL on the EuroQol 5-dimension 5-level (EQ-5D-5L)

Time frame
Recorded at enrolment and at 4 and 12 weeks, 12 and 24 months post-randomization
3

Global Perceived Effect scale

Global perceived effect of the treatment will be assessed using single question with seven-point descriptive scaling with the answers

Time frame
Recorded at 4 and 12 weeks, 12 and 24 months post-randomization
4

Sagittal balance

Full-length 36" lateral scoliosis radiographs taken with hands placed on the clavicles will be obtained to measure Pelvic Incidence, Pelvic Tilt, Sacral Slope, C7-Plumb Line and Lumbar Lordosis/Thoracic Kyphosis both preoperatively and after 12 months

Time frame
Recorded at enrolment and 12 months post-randomization

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.